Back to ALTH Stock Lookup

ALTH – FDA

Aug 29, 2012 06:51 AM FTC Clears Spectrum's (SPPI) Acquisition of Allos (ALTH) Acquisition
Apr 20, 2012 09:55 AM Allos (ALTH) Says CHMP Reaffirms Negative Opinion on FOLOTYN MAA
Jan 30, 2012 08:31 AM Allos Therapeutics (ALTH) Submits Request for Re-Examination of FOLOTYN Negative Opinion by CHMP
Jan 20, 2012 07:44 AM Allos Therapeutics (ALTH) Says EMA CHMP Recommends Against Approval for FOLOTYN as PTCL Treatment
Jun 20, 2011 06:36 AM Allos Therapeutics (ALTH) Updates on FOLOTYN PROPEL
Jun 17, 2011 06:51 AM Allos (ALTH) Reports Publication of Encouraging FOLOTYN Data
Jun 16, 2011 07:11 AM Allos (ALTH) Updates on COMPLETE for Futher PTCL Treatment Understanding
Jun 8, 2011 09:03 AM Allos Therapeutics (ALTH) Presents FOLOTYN Data at EHA Congress
Dec 6, 2010 09:02 AM Ariad (ARIA) May Have Been Best at ASH Meeting
Dec 6, 2010 07:34 AM Allos Therapeutics (ALTH) Presents Strong Data from PROPEL of FOLOTYN in Patients with Relapsed PTCL
Dec 6, 2010 07:31 AM Allos Therapeutics (ALTH) Announces Encouraging Data from FOLOTYN PROPEL in Patients with PTCL
Dec 1, 2010 08:08 AM Allos Therapeutics (ALTH) To Present Data for FOLOTYN Phase 2b in Patients with Stage IIIB/IV NSCLC
Nov 19, 2010 09:13 AM Allos Therapeutics (ALTH) To Present Five Abstracts of FOLOTYN Data on Blood Cancers at 52nd ASH Annual Meeting
Oct 15, 2010 09:10 AM Allos Therapeutics (ALTH) Announces the EC Grants Orphan Designation to HL Treatment Pralatrexate
Jul 28, 2010 08:31 AM Allos Therapeutics (ALTH) Announces Strong Results in FOLOTYN Phase 2b
Jun 17, 2010 09:06 AM Allos Therapeutics (ALTH) Gets Orphan Designation from EC for CTCL Treatment Pralatrexate
Jun 11, 2010 11:49 AM Allos Therapeutics (ALTH) Presents Data from FOLOTYN Phase 1
Jun 7, 2010 08:44 AM Allos Therapeutics (ALTH) Announces Strong Data Related to PROPEL Trial of FOLOTYN In Patients with PTCL
May 18, 2010 08:24 AM Allos Therapeutics (ALTH) Gets Orphan Drug Designation from U.S. FDA for Pralatrexate
Dec 7, 2009 06:52 AM Allos Thera (ALTH) Updates on Pivotal PROPEL Trail of FOLOTYN
Sep 25, 2009 10:03 AM Shares of Allos Therapeutics (ALTH) Give Back After Strong Opening
Sep 25, 2009 08:17 AM Allos Therapeutics' (ALTH) FOLOTYN First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Sep 23, 2009 08:20 AM Allos Therapeutics (ALTH) October volatility elevated into FDA meeting
Sep 3, 2009 08:34 AM Allos Therapeutics (ALTH) Higher Following FDA Panel Recommendation of FOLOTYN
Sep 2, 2009 04:57 PM FDA Panel Backs Allos Therapeutics (ALTH) lymphoma drug Folotyn
Aug 10, 2009 11:01 AM Allos Therapeutics (ALTH) Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Jun 1, 2009 07:10 AM Allos Therapeutics (ALTH) Updates Phase 2 PROPEL Study At ASCO
May 26, 2009 08:16 AM Allos Therapeutics (ALTH) Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
Mar 17, 2009 08:30 AM Allos Therapeutics' (ALTH) Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer
Feb 4, 2009 07:02 AM Allos Therapeutics (ALTH) Announces Positive Phase 2 PROPEL Trial of Pralatrexate
Dec 8, 2008 08:56 AM Allos Therapeutics (ALTH) Reports Preliminary Top Line Results from PROPEL
Dec 1, 2008 04:06 PM Allos Therapeutics (ALTH) Granted FDA Orphan Drug Designation for Treatment of Patients with Follicular Lymphoma
Nov 24, 2008 04:41 PM Allos Therapeutics (ALTH) Announces FDA Grants Orphan Drug Status for Pralatrexate
Apr 22, 2008 08:33 AM Allos Therapeutics (ALTH) Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Jun 19, 2007 07:15 AM Allos Therapeutics (ALTH) Said Efaproxyn Failed to Meet Primary Endpoint
May 31, 2007 04:44 PM Allos Therapeutics (ALTH) Initiates Phase I/II Study of PDX and Gemcitabine
Dec 11, 2006 11:54 AM Allos Therapeutics (ALTH) Announces Presentation of Phase 1/2 Trials of PDX in Patients with Relapsed or Refractory non-Hodgkin's Lymphoma and Hodgkin's Disease
Dec 5, 2006 01:48 PM Needham Highlights Biotech Companies Presenting at the Upcoming American Society of Hematology
Nov 9, 2006 02:02 PM Allos Therapeutics (ALTH) Says Phase 1/2 Results of PDX to be Presented at American Society of Hematology Annual Meeting
Oct 3, 2006 08:05 AM Allos Therapeutics (ALTH) Receives FDA Fast Track Designation for PDX
Jun 28, 2006 12:34 PM Needham Analyst Discusses Partnering Opportunities in Biotech
Jun 5, 2006 08:09 AM Allos Therapeutics (ALTH) Announces Positive Pre-Clinical Study of EFAPROXYN
Apr 4, 2006 07:14 AM Allos Therapeutics (ALTH) Interim Analysis Supports Continuation of Phase 3 Trial
Mar 10, 2006 10:25 AM Needham issues a note focusing on biotech stocks with upcoming milestones in March
Feb 14, 2006 08:05 AM ALTH Said Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine
Dec 12, 2005 08:10 AM ALTH Said EFAPROXYN Extends Survival n Patients With Brain Metastases
Sep 1, 2005 08:18 AM ALTH Said EFAPROXYN May Improve Survival in Lung Cancer Patients

Back to ALTH Stock Lookup